Athira Pharma (NASDAQ:LONA) Cut to Sell at Wall Street Zen

Wall Street Zen lowered shares of Athira Pharma (NASDAQ:LONA) from a hold rating to a sell rating in a research note released on Saturday.

Several other brokerages also recently commented on LONA. Weiss Ratings initiated coverage on Athira Pharma in a research note on Wednesday, February 11th. They set a “sell (d-)” rating for the company. Cantor Fitzgerald began coverage on shares of Athira Pharma in a report on Thursday, February 26th. They set an “overweight” rating on the stock. Finally, Mizuho raised shares of Athira Pharma from a “neutral” rating to an “outperform” rating and set a $10.00 price objective for the company in a research note on Thursday, February 19th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $10.00.

Athira Pharma Stock Performance

NASDAQ LONA opened at $5.72 on Friday. Athira Pharma has a fifty-two week low of $2.20 and a fifty-two week high of $8.36.

Athira Pharma Company Profile

Athira Pharma, traded as LONA on the NASDAQ, is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule therapeutics intended to restore neuronal health and function in neurodegenerative and cognitive disorders. The company’s research approach centers on modulating pathways involved in synaptic repair and neurotrophic signaling to address underlying neuronal dysfunction rather than solely treating symptoms.

Athira’s lead investigational therapy is fosgonimeton (ATH-1017), a small-molecule candidate designed to potentiate hepatocyte growth factor (HGF)/MET pathway signaling with the aim of improving synaptic connectivity and cognitive performance in patients with conditions such as Alzheimer’s disease and related cognitive impairments.